Bayer ($BAYZF) - Big Pharma's Q3 2010 Earnings Report

FiercePharma says: Bayer earned €280 million this quarter compared to €249 million the previous year, thanks primarily to its farm products and high-tech material divisons, as drug sales slowed despite good growth in emerging markets. Its birth control pill, Yaz, suffered due to increased generic competition. The company set aside €436 million for U.S. lawsuits, including €50 million for Yaz and Yasmin litigation.

Highlights

  • Sales grow by 16.1 percent to EUR 8,581 million
  • EBITDA before special items up 10.5 percent to €1.656 million
  • Core earnings per share increase by 21.8 percent to €0.95
  • Provisions of €436 million established for litigations
  • Net financial debt reduced by €1.6 billion to €9.1 billion
  • Group outlook for 2010 confirmed

See Bayer's current stock quote from CNN Money

Bayer's website: http://www.bayer.com/
Full release: Bayer earnings release

Bayer ($BAYZF) - Big Pharma's Q3 2010 Earnings Report
Read more on

Suggested Articles

The triple combo era in cystic fibrosis is here thanks to Vertex' new OK. Five months ahead of schedule, the FDA green-lighted Trikafta Monday.

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.